Previous close | 2.0600 |
Open | 1.9500 |
Bid | 2.0000 x 100 |
Ask | 2.1200 x 100 |
Day's range | 1.9200 - 2.1300 |
52-week range | 0.4500 - 3.2500 |
Volume | |
Avg. volume | 369,832 |
Market cap | 72.346M |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
LA JOLLA, Calif., March 25, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
LA JOLLA, Calif., March 22, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.